Artículos de revistas sobre el tema "Eribulin Mesylate"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Eribulin Mesylate".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Huyck, Timothy K., William Gradishar, Fil Manuguid y Peter Kirkpatrick. "Eribulin mesylate". Nature Reviews Drug Discovery 10, n.º 3 (marzo de 2011): 173–74. http://dx.doi.org/10.1038/nrd3389.
Texto completoJain, Sarika y Linda T. Vahdat. "Eribulin Mesylate". Clinical Cancer Research 17, n.º 21 (22 de agosto de 2011): 6615–22. http://dx.doi.org/10.1158/1078-0432.ccr-11-1807.
Texto completoEdwards, Michael S., Dominic A. Solimando y J. Aubrey Waddell. "Eribulin Mesylate and Denosumab". Hospital Pharmacy 46, n.º 4 (abril de 2011): 247–53. http://dx.doi.org/10.1310/hpj4604-247.
Texto completoVerdaguer, Helena, Idoia Morilla y Ander Urruticoechea. "Eribulin Mesylate in Breast Cancer". Women's Health 9, n.º 6 (noviembre de 2013): 517–26. http://dx.doi.org/10.2217/whe.13.61.
Texto completoNieder, Carsten, Gro Aandahl y Astrid Dalhaug. "A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate". Case Reports in Oncological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/537183.
Texto completoBarnato, Sara E., Jacqueline Sara Jeruss, Kevin P. Bethke, Nora M. Hansen, Seema Ahsan Khan, Jamie H. Von Roenn, Steven T. Rosen et al. "Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): TPS1134. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1134.
Texto completoPullela, Srinivas Venkata, Vinod Acharya, Nagarjuna Reddy, Jayvant Harlikar, Amar Kulkarni, Rakesh Chavan, Ajay Yadav, Shuvendu Manna y Angshuman Ghosh. "Structural corroboration of two important building blocks of the anticancer drug eribulin mesylate through two-dimensional NMR and single-crystal X-ray diffraction studies". Acta Crystallographica Section C Structural Chemistry 72, n.º 1 (1 de enero de 2016): 14–20. http://dx.doi.org/10.1107/s2053229615022305.
Texto completoNasim, Muhammad Yaser, Ruth Plummer, T. R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi et al. "A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 2552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2552.
Texto completoIwamoto, Mitsuhiko, Nayuko Sato, Risa Terasawa, Hiroya Fujioka, Yuko Takahashi, Kosei Kimura, Satoru Tanaka y Kazuhisa Uchiyama. "Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): TPS1140. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps1140.
Texto completoRaftopoulos, Harry, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones y Daniel Peter Petrylak. "Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e19145-e19145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19145.
Texto completoChiba, Hiroyuki y Katsuya Tagami. "Research and Development of HALAVEN(Eribulin Mesylate)". Journal of Synthetic Organic Chemistry, Japan 69, n.º 5 (2011): 600–610. http://dx.doi.org/10.5059/yukigoseikyokaishi.69.600.
Texto completoFujimoto, Etsuko, Kazuhiro Takehara, Tamaki Tanaka, Takanori Yokoyama, Katsuyuki Tomono, Mika Okazawa-Sakai, Shinichi Okame, Yoshifumi Sugawara y Norihiro Teramoto. "Uterine leiomyosarcoma well-controlled with eribulin mesylate". International Cancer Conference Journal 8, n.º 1 (12 de noviembre de 2018): 33–38. http://dx.doi.org/10.1007/s13691-018-0350-1.
Texto completoVahdat, Linda T., Agustin Garcia, Charles L. Vogel, Christine M. Pellegrino, Deborah L. Lindquist, Joseph A. Sparano, Prashanth Gopalakrishna y Nicholas Iannotti. "Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study." Journal of Clinical Oncology 30, n.º 27_suppl (20 de septiembre de 2012): 121. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.121.
Texto completoLiu, Liping, Zhe-Yu Hu, Ning Xie, Xiaohong Yang, Huawu Xiao, Jing Li, Can Tian et al. "Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 1094. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1094.
Texto completoSenapati, Sibadatta y Chepuri V. Ramana. "A concise/catalytic approach for the construction of the C14–C28 fragment of eribulin". Organic & Biomolecular Chemistry 19, n.º 20 (2021): 4542–50. http://dx.doi.org/10.1039/d1ob00661d.
Texto completoGluck, Stefan, Joyce O'Shaughnessy, Kristi McIntyre, Lee Steven Schwartzberg, Sharon Wilks, Shannon Leigh Huggins-Puhalla, Erhan Berrak, James X. Song, David Cox y Linda T. Vahdat. "Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies." Journal of Clinical Oncology 32, n.º 26_suppl (10 de septiembre de 2014): 140. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.140.
Texto completoXie, Xiao-Feng, Jia-Yi Huang, Li-Ping Chen, Xiao-Feng Lan, Qiu-Yi Zhang, Lin Song, Xue Bai y Cai-Wen Du. "Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report". Journal of International Medical Research 50, n.º 7 (julio de 2022): 030006052210900. http://dx.doi.org/10.1177/03000605221090097.
Texto completoO'Shaughnessy, Joyce, Shannon Leigh Huggins-Puhalla, Sharon Wilks, Adam Brufsky, Lee Steven Schwartzberg, Erhan Berrak, James X. Song, David Cox y Linda T. Vahdat. "Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study." Journal of Clinical Oncology 32, n.º 26_suppl (10 de septiembre de 2014): 139. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.139.
Texto completoMoore, M. J., P. Tang, D. Renouf, P. Major, D. Hedley, V. Paterson, L. Wang, B. Dhesy-Thind, B. Southwood y L. Doyle. "A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): e15634-e15634. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15634.
Texto completoVahdat, Linda T., Brian Pruitt, Carol J. Fabian, Ragene R. Rivera, David A. Smith, Elizabeth Tan-Chiu, Jonathan Wright et al. "Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane". Journal of Clinical Oncology 27, n.º 18 (20 de junio de 2009): 2954–61. http://dx.doi.org/10.1200/jco.2008.17.7618.
Texto completoKo, Hyemi, Myungsun Lee, Eunyoung Cha, Jiyoung Sul, Junbeom Park y Jinsun Lee. "Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation". Medicina 58, n.º 4 (15 de abril de 2022): 547. http://dx.doi.org/10.3390/medicina58040547.
Texto completoWilks, Sharon y Kristi Mcintyre. "Case Studies in the Management of Metastatic Breast Cancer with Eribulin". Clinical Medicine Insights: Oncology 9 (enero de 2015): CMO.S27962. http://dx.doi.org/10.4137/cmo.s27962.
Texto completoHussar, Daniel A. y Lisa Pasco. "New drugs: Ceftaroline fosamil, pegloticase, and eribulin mesylate". Journal of the American Pharmacists Association 51, n.º 2 (marzo de 2011): 316–19. http://dx.doi.org/10.1331/japha.2011.11511.
Texto completoWitteveen, P., S. Marchetti, M. Mergui-Roelvink, L. Reyderman, W. Copalu, J. Wanders, A. Jenner, G. Edwards, J. H. Schellens y E. E. Voest. "Eribulin mesylate pharmacokinetics in patients with hepatic impairment." Journal of Clinical Oncology 28, n.º 15_suppl (20 de mayo de 2010): 2582. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2582.
Texto completoCigler, Tessa y Linda T. Vahdat. "Eribulin mesylate for the treatment of breast cancer". Expert Opinion on Pharmacotherapy 11, n.º 9 (7 de mayo de 2010): 1587–93. http://dx.doi.org/10.1517/14656566.2010.486790.
Texto completoNelson, Ariel Ann, Shivaprasad Manjappa, Yuvraj Choudhary, Cheryl L. Thompson, Jeanine Agler, Bethany Lawrence, Manmeet Singh Ahluwalia y Paula Silverman. "Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC)." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e12571-e12571. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e12571.
Texto completoMiano, Salvatora Tindara, Edoardo Francini, Roberto Petrioli y Guido Francini. "A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient". Future Oncology 16, n.º 1s (enero de 2020): 33–38. http://dx.doi.org/10.2217/fon-2019-0600.
Texto completoJansen, M., M. Vernaz-Gris, C. DesJardins, N. Wong, M. Campone, J. Cortes, J. Wanders, D. Shuster y E. Fuseau. "Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): 2524. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2524.
Texto completoKok, Victor C. "Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings". Breast Cancer: Basic and Clinical Research 9 (enero de 2015): BCBCR.S32787. http://dx.doi.org/10.4137/bcbcr.s32787.
Texto completoCortes, Javier, Linda Vahdat, Joanne L. Blum, Chris Twelves, Mario Campone, Henri Roché, Thomas Bachelot et al. "Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine". Journal of Clinical Oncology 28, n.º 25 (1 de septiembre de 2010): 3922–28. http://dx.doi.org/10.1200/jco.2009.25.8467.
Texto completoSrinivasa, BJ, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia et al. "Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience". Clinical Medicine Insights: Oncology 12 (1 de enero de 2018): 117955491878247. http://dx.doi.org/10.1177/1179554918782475.
Texto completoChandrasekhar, Srivari, Vikram Gaddam, Lavanya Nadella, Genji Sukumar y Prathama Mainkar. "Stereoselective Synthesis of Northern Fragment of Eribulin Mesylate from d-Mannose". Synthesis 50, n.º 09 (21 de febrero de 2018): 1901–6. http://dx.doi.org/10.1055/s-0036-1591769.
Texto completoTwelves, Chris, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus y Peter A. Kaufman. "Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer". Breast Cancer: Basic and Clinical Research 10 (enero de 2016): BCBCR.S39615. http://dx.doi.org/10.4137/bcbcr.s39615.
Texto completoXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy y Naoto T. Ueno. "Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines". Biomedicines 11, n.º 3 (28 de febrero de 2023): 735. http://dx.doi.org/10.3390/biomedicines11030735.
Texto completoPatil, S., R. Thippeswamy, HP Shashidara, CT Satheesh, H. Vittal y S. Mishra. "Eribulin mesylate in Indian patients: A single center experience". Indian Journal of Cancer 52, n.º 3 (2015): 297. http://dx.doi.org/10.4103/0019-509x.176735.
Texto completoSimoneaux, Richard. "Eribulin Mesylate Plus Pembrolizumab Shows Encouraging Efficacy in TNBC". Oncology Times 40 (febrero de 2018): 15–16. http://dx.doi.org/10.1097/01.cot.0000530523.23834.dc.
Texto completoLee, Hyoseon, Yongseo Park, Heesun Jung, Seong Take Kim, Seunghui Sin, Eunjung Ko, In-Soo Myeong et al. "Synthesis of the C1–C13 fragment of eribulin mesylate". Tetrahedron 75, n.º 33 (agosto de 2019): 4570–76. http://dx.doi.org/10.1016/j.tet.2019.06.050.
Texto completoNakai, M., M. Suzuki, T. Kurita, K. Yanagihara y H. Takei. "Eribulin Mesylate improving survival outcomes of metastatic breast cancer". Breast 32 (marzo de 2017): S67. http://dx.doi.org/10.1016/s0960-9776(17)30228-x.
Texto completoChiba, Hiroyuki y Katsuya Tagami. "ChemInform Abstract: Research and Development of HALAVEN (Eribulin Mesylate)". ChemInform 42, n.º 50 (17 de noviembre de 2011): no. http://dx.doi.org/10.1002/chin.201150215.
Texto completoPapadaki, Maria A., Anastasia Mala, Aikaterini C. Merodoulaki, Maria Vassilakopoulou, Dimitrios Mavroudis y Sofia Agelaki. "Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate". Cancers 14, n.º 16 (12 de agosto de 2022): 3903. http://dx.doi.org/10.3390/cancers14163903.
Texto completoTremblay, Gabriel, Unnati Majethia, Ilias Kontoudis y Jesús De Rosendo. "Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy". Journal of Health Economics and Outcomes Research 3, n.º 2 (21 de octubre de 2015): 180–93. http://dx.doi.org/10.36469/9834.
Texto completoSM, Bindu, PL Rema y Praveen Jacob Ninan. "Eribulin Mesylate in Treated Metastatic Breast Cancer Patients: A Retrospective Study of Tumor Response and Adverse Effects". Galore International Journal of Health Sciences and Research 6, n.º 2 (15 de junio de 2021): 37–44. http://dx.doi.org/10.52403/gijhsr.20210405.
Texto completoDemetri, George D., Patrick Schöffski, Giovanni Grignani, Jean-Yves Blay, Robert G. Maki, Brian A. Van Tine, Thierry Alcindor et al. "Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine". Journal of Clinical Oncology 35, n.º 30 (20 de octubre de 2017): 3433–39. http://dx.doi.org/10.1200/jco.2016.71.6605.
Texto completoBlum, J. L., B. Pruitt, C. J. Fabian, R. R. Rivera, D. E. Shuster, N. L. Meneses, K. Chandrawansa, F. Fang, S. Z. Fields y L. Vahdat. "Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 1034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1034.
Texto completoAdamo, Vincenzo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro et al. "Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study". Therapeutic Advances in Medical Oncology 11 (enero de 2019): 175883591989575. http://dx.doi.org/10.1177/1758835919895755.
Texto completoMcBride, Ali, Claudio Faria, Xuan Li y Annette Powers. "Eribulin treatment patterns in patients with and without prior anthracycline use." Journal of Clinical Oncology 32, n.º 30_suppl (20 de octubre de 2014): 292. http://dx.doi.org/10.1200/jco.2014.32.30_suppl.292.
Texto completoHensley, M. L., S. Kravetz, C. Sima, W. Tew, L. Pereira, P. Sabbatini, C. Whalen, C. A. Aghajanian, C. Zarwan y S. Berlin. "Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): A CTEP-sponsored phase II study". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): 5561. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5561.
Texto completoTraina, Tiffany A., Clifford Hudis, Robert Lehman, Jessicca Rege, Wenquan Wang, David Cox y Andrew David Seidman. "A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): TPS1145. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1145.
Texto completoFilonenko, D. V. y A. V. Belonogov. "ERIBULIN MESYLATE: OUR EXPERIENCE IN A REAL-LIFE CLINICAL SETTING". Malignant tumours 7, n.º 4 (1 de enero de 2017): 21–28. http://dx.doi.org/10.18027/2224-5057-2017-7-4-21-28.
Texto completoAditya, Suruchi. "Eribulin mesylate: A new therapeutic option for metastatic breast cancer". Journal of Basic and Clinical Reproductive Sciences 2, n.º 1 (2013): 6. http://dx.doi.org/10.4103/2278-960x.112571.
Texto completo